86 related articles for article (PubMed ID: 19528520)
21. Cost-effectiveness of carbamazepine in epilepsy.
Heaney D; Sander JW
Expert Rev Pharmacoecon Outcomes Res; 2006 Feb; 6(1):13-8. PubMed ID: 20528532
[TBL] [Abstract][Full Text] [Related]
22. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
Lessing C; Ashton T; Davis P
Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
[TBL] [Abstract][Full Text] [Related]
23. Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs.
Hottinger M; Liang BA
Am J Law Med; 2012; 38(4):667-89. PubMed ID: 23356099
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes associated with brand-to-generic phenytoin interchange.
Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs.
Bautista RE; Gonzales W; Jain D
Epilepsy Res; 2011 Jun; 95(1-2):158-67. PubMed ID: 21530177
[TBL] [Abstract][Full Text] [Related]
26. Switching from brand-name to generic psychotropic medications: a literature review.
Desmarais JE; Beauclair L; Margolese HC
CNS Neurosci Ther; 2011 Dec; 17(6):750-60. PubMed ID: 21114789
[TBL] [Abstract][Full Text] [Related]
27. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation.
Vadney VJ; Kraushaar KW
Ment Retard; 1997 Dec; 35(6):468-72. PubMed ID: 9425876
[TBL] [Abstract][Full Text] [Related]
28. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
29. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
[TBL] [Abstract][Full Text] [Related]
30. Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.
Meijboom RW; Gardarsdottir H; Becker ML; Movig KLL; Kuijvenhoven J; Egberts TCG; Giezen TJ
Therap Adv Gastroenterol; 2023; 16():17562848231197923. PubMed ID: 37706094
[TBL] [Abstract][Full Text] [Related]
31. Attitudes towards the switching of anti-epileptic medications in pharmacies: the patients' perspective.
Bożek M; Kurkowska-Jastrzebska I; Krzystanek E; Bienkowski P; Konopko M; Sienkiewicz-Jarosz H
Postep Psychiatr Neurol; 2023 Mar; 32(1):12-17. PubMed ID: 37287735
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Basis of Generic Substitution of Antiseizure Medications.
Elmer S; Reddy DS
J Pharmacol Exp Ther; 2022 May; 381(2):188-196. PubMed ID: 35241634
[TBL] [Abstract][Full Text] [Related]
33. Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.
Weitzel J; Erzkamp S; Langer K; Rose O
Int J Clin Pharm; 2020 Apr; 42(2):393-417. PubMed ID: 32274633
[TBL] [Abstract][Full Text] [Related]
34. Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
.
Reigner B; Grange S; Bentley D; Banken L; Abt M; Hughes R; Scheubel E; Guentert TW
Int J Clin Pharmacol Ther; 2019 Oct; 57(10):506-519. PubMed ID: 31397274
[TBL] [Abstract][Full Text] [Related]
35. Nocebo in Biosimilars and Generics in Neurology: A Systematic Review.
Spanou I; Mavridis T; Mitsikostas DD
Front Pharmacol; 2019; 10():809. PubMed ID: 31396084
[No Abstract] [Full Text] [Related]
36. Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study.
Fife D; Cepeda MS; Baseman A; Richards H; Hu P; Starr HL; Sena AG
PLoS One; 2018; 13(2):e0193453. PubMed ID: 29489906
[TBL] [Abstract][Full Text] [Related]
37. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
Bosak M; Słowik A; Turaj W
Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
Maniadakis N; Kourlaba G; Shen J; Holtorf A
BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
[TBL] [Abstract][Full Text] [Related]
39. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
[TBL] [Abstract][Full Text] [Related]
40. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature.
Atif M; Azeem M; Sarwar MR
Springerplus; 2016; 5():182. PubMed ID: 27026878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
